SLN.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications...

Stats
Today's Volume	913 528
Average Volume	104 775
Market Cap	0.00
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.110
ATR14	£0 (0.00%)

Silence Therapeutics PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Silence Therapeutics PLC Financials

Annual	2020
Revenue:	£5.48M
Gross Profit:	£1.72M (31.34 %)
EPS:	£-0.398

Q3	2021
Revenue:	£3.16M
Gross Profit:	£1.10M (34.98 %)
EPS:	£-0.111

Q2	2018
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£0

Q2	2017
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£0

Financial Reports:

No articles found.

Silence Therapeutics PLC

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.